Results 61 to 70 of about 19,899 (238)

microRNA‐7‐5p and α‐Synuclein SAA Predict Parkinson's Disease Phenoconversion

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Corroborate blood neuron‐derived extracellular vesicle (NDEV) alpha‐synuclein (αSyn), the CSF αSyn seed amplification assay (αSyn‐SAA), and blood microRNA‐7‐5p (miR‐7‐5p) as markers for Parkinson's disease (PD) phenoconversion and determine if combining these markers would help select subjects who would be more likely to phenoconvert.
Shayan Zadegan, Praveen Velammal, Kanmani Muthiah, Madhu Jatty, Christopher Adams   +4 more
wiley   +1 more source

LRRK2 genetics and expression in the Parkinsonian brain [PDF]

, 2010
Mutations in LRRK2 have been established as a common genetic cause of Parkinson’s disease (PD). Variation in gene expression of PARK loci has previously been demonstrated in PD pathogenesis, although it has not been described in detail for LRRK2 ...
Sharma, S.
core  

Analysis of Lrrk2 R1628p as a Risk Factor for Parkinson's Disease

, 2009
Common genetic variants that increase the risk for Parkinson 's disease may differentiate patient subgroups and influence future individualized therapeutic strategies. Herein we show evidence for leucine-rich repeat kinase 2 (LRRK2) c.
Ross, Owen A.; Wu, Yih-Ru; Lee, Mei-Ching; Funayama, Manabu; Chen, Meng-Ling; Soto, Alexandra I.; Mata, Ignacio F.; Lee-Chen, Guey-Jen; Chen, Chiung Mei; Tang, Michelle; Zhao, Yi; Hattori, Nobutaka; Farrer, Matthew J.; Tan, Eng-King; Wu, Ruey-Meei, 吳逸如;李美靜;陳孟伶;李桂楨;陳瓊美;吳瑞美   +1 more
core   +1 more source

Fluorescent tagging of endogenous LRRK2 to identify potential regulators of LRRK2 protein degradation [PDF]

, 2023
Parkinson’s Disease (PD) is a progressive neurodegenerative disorder that affects more than 10 million people worldwide. While most cases of PD are sporadic, point mutations in Leucine-Rich Repeat Kinase (LRRK2) have been determined to be the most common
Yang, Young (Emily)
core   +1 more source

The WD40 domain is required for LRRK2 neurotoxicity. [PDF]

PLoS ONE, 2009
BACKGROUND:Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of Parkinson disease (PD). LRRK2 contains an "enzymatic core" composed of GTPase and kinase domains that is flanked by leucine-rich repeat (LRR) and WD40 ...
Nathan D Jorgensen, Yong Peng, Cherry C-Y Ho, Hardy J Rideout, Donald Petrey, Peng Liu, William T Dauer   +6 more
doaj   +1 more source

Aberrant Patterns of Sensory-Evoked Activity in the Olfactory Bulb of LRRK2 Knockout Mice

Cells, 2021
The LRRK2 gene is the major genetic determinant of familiar Parkinson’s disease (PD). Leucine-rich repeat kinase 2 (LRRK2) is a multidomain protein involved in several intracellular signaling pathways.
Andrea Maset, Marco Albanesi, Antonio di Soccio, Martina Canova, Marco dal Maschio, Claudia Lodovichi   +5 more
doaj   +1 more source

LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease

Translational Neurodegeneration, 2022
Mutations in the leucine-rich repeat kinase 2 gene (LRRK2) are one of the most frequent genetic causes of both familial and sporadic Parkinson’s disease (PD). Mounting evidence has demonstrated pathological similarities between LRRK2-associated PD (LRRK2-
Eunice Eun Seo Chang, Philip Wing-Lok Ho, Hui-Fang Liu, Shirley Yin-Yu Pang, Chi-Ting Leung, Yasine Malki, Zoe Yuen-Kiu Choi, David Boyer Ramsden, Shu-Leong Ho   +8 more
doaj   +1 more source

Lrrk2 Mutation in Familial Parkinson's Disease in a Taiwanese Population: Clinical, Pet, and Functional Studies

, 2011
Pathogenic mutations in leucine-rich repeat kinase 2 (LRRK2) cause autosomal-dominant familial Parkinson's disease (PD). We performed clinical, imaging, and molecular functional studies in one family with the R1441H and six families with the G2385R ...
林靜嫻;曾凱元;余勁毅;戴春暉;吳瑞美, LIN, CHIN-HSIEN;TZEN, KAI-YUAN;YU, CHIN-YI;TAI, CHUN-HWEI;WU, RUEY-MEEI   +1 more
core   +1 more source

α-synuclein RT-QuIC in cerebrospinal fluid of LRRK2 linked Parkinson’s disease [PDF]

, 2019
Background<jats:p/>Leucine‐rich kinase 2 (LRRK2)‐linked Parkinson's disease (PD) is clinically indistinguishable from idiopathic PD (IPD). A pleiotropic neuropathology has been recognized but the majority of studies in LRRK2 p.G2019S patients ...
Garrido, Alicia, Garrido Pla, Alicia, Alicia Garrido, Alison Green, Ávila Rivera, Maria Asunción, Barcelona LRRK2 Study Group, ?, ?, Tolosa, Eduardo, Fairfoul, Graham; id_orcid, Maria José Martí, Marti, MJ, Fairfoul, Graham, Martí Domènech, Ma. Josep, Green, Alison, Graham Fairfoul, Eduardo S. Tolosa   +15 more
core   +1 more source

G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage

npj Parkinson's Disease
Pathogenic mutations in LRRK2 cause Parkinson’s disease (PD). The G2019S variant is the most common, which results in abnormally high kinase activity. Compounds that target LRRK2 kinase activity are currently being developed and tested in clinical trials.
Nicholas Pena, Tara Richbourg, Claudia P. Gonzalez-Hunt, Rui Qi, Paul Wren, Carrolee Barlow, Natalie F. Shanks, Holly J. Carlisle, Laurie H. Sanders   +8 more
doaj   +1 more source